DexCom

DXCM

Market cap $25.7B

One way to earn above-average market returns -- which isn't always easy -- is to invest in companies that have lagged the market but are likely to recover over the long run. As the basic investing maxim goes, "Buy low, sell high.

NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% gross margin, and 21% operating margin, supported by recurring sensor sales and innovation. Stelo opens a new market, providing a gateway to the G7 ecosystem and offering a scalable, user-friendly platform with medical-grade positioning.

NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2025 financial results after market close on Thursday, October 30, 2025. Management will hold a conference call to review the company's third quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and wil.

NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders.

NEW YORK , Sept. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM).

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM).